Vaccine to prevent enterotoxigenic E. coli (ETEC) diarrhea
Evaluation of Memory Responses and Biomarkers from a Phase IEnterotoxigenic Escherichia coli (ETEC) Intramuscular SubunitVaccine with dmLT Adjuvant
['FUNDING_R01'] · TULANE UNIVERSITY OF LOUISIANA · NIH-11164702
This project looks at how an injectable ETEC vaccine given with the dmLT helper substance helps people at risk—like young children, travelers, and military personnel—build lasting antibody and cellular memory against E. coli.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TULANE UNIVERSITY OF LOUISIANA (nih funded) |
| Locations | 1 site (NEW ORLEANS, UNITED STATES) |
| Trial ID | NIH-11164702 on ClinicalTrials.gov |
What this research studies
If you or someone like you joined the earlier Phase 1 vaccine effort, researchers will analyze stored blood samples to measure antibody levels and immune memory cells. They will examine serum antibodies and peripheral blood mononuclear cells (PBMCs) to study how different vaccine doses and the dmLT adjuvant affect durability and diversity of the response. Laboratory work will include antibody assays and cellular analyses to identify biomarkers and molecular signals linked to longer-lasting protection. The team aims to find markers that explain why some people make stronger or more durable immune memory.
Who could benefit from this research
Good fit: People most likely to benefit include young children in ETEC-endemic areas, travelers to regions with ETEC risk, and deployed military personnel.
Not a fit: People whose diarrhea is caused by non-ETEC pathogens or who cannot mount immune responses (for example, severely immunocompromised individuals) may not receive direct benefit from this vaccine approach.
Why it matters
Potential benefit: If successful, the work could help design better ETEC vaccines that give longer-lasting protection for children, travelers, and deployed personnel.
How similar studies have performed: An earlier Phase 1 trial found the vaccine was safe and produced strong antibody responses, but the detailed memory and biomarker analyses planned here are new.
Where this research is happening
NEW ORLEANS, UNITED STATES
- TULANE UNIVERSITY OF LOUISIANA — NEW ORLEANS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NORTON, ELIZABETH B — TULANE UNIVERSITY OF LOUISIANA
- Study coordinator: NORTON, ELIZABETH B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.